PML and acute promyelocytic leukemia: Despite its carcinogenic potential, AsIII has also been used as a treatment option for APL, which is frequently associated with a gene fusion involving the retinoic acid receptor alpha (RARA) and the promyelocytic leukemia protein (PML) gene [119].